The company manufactures and exports precision-engineered automotive components and a wide range of agricultural machinery, such as tillers and harvesters, under the Swan Agro brand.
The company operates in a highly competitive, capital-intensive industry with low net margins (sub-5%) and negative EPS growth over the period, suggesting a lack of pricing power or cost advantage. While the Swan Agro brand provides some market presence, the financial results do not corroborate a durable competitive advantage.
Capital has been primarily deployed into capacity expansion and debt repayment following an IPO. While ROCE is respectable at 16.9%, the sharp decline in EPS suggests that recent reinvestments have yet to translate into per-share value for owners.
The investment failed because the company remained a commodity producer trapped in a capital-intensive cycle with no pricing power. Despite growing the top line, the negative EPS growth observed in the filings accelerated as rising promoter remuneration and related-party transactions drained the meager 4.8% net margins. The lack of internal controls and tax disputes eventually culminated in a liquidity crunch, where high inventory levels and debt service requirements overwhelmed the stagnant cash flow, leaving shareholders with a business that destroys value with every new rupee of capital deployed.
RichFakir rates New Swan Multitech Ltd's business quality as mediocre — 49/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, New Swan Multitech Ltd is trading about 54% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on New Swan Multitech Ltd is: Not rated. A mediocre business at a cheap price — it does not make our shortlist right now.
RichFakir's educational estimate of New Swan Multitech Ltd's fair value is about ₹73 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →